MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
Biogen Accounts Receivables 2011-2025 | BIIB
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Biogen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.4 B | 1.66 B | 1.7 B | 1.55 B | 1.91 B | 1.88 B | 1.96 B | 1.79 B | 1.44 B | 1.23 B | 1.29 B | 824 M | 687 M | 585 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.96 B | 585 M | 1.42 B |
Quarterly Accounts Receivables Biogen
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 1.63 B | 1.7 B | 1.57 B | 1.57 B | 1.63 B | 1.55 B | 1.72 B | 1.69 B | 1.55 B | 1.91 B | 1.91 B | 1.91 B | 1.91 B | 1.88 B | 1.88 B | 1.88 B | 1.88 B | 1.96 B | 1.96 B | 1.96 B | 1.96 B | 1.79 B | 1.79 B | 1.79 B | 1.79 B | 1.44 B | 1.44 B | 1.44 B | 1.44 B | 1.23 B | 1.23 B | 1.23 B | 1.23 B | 1.29 B | 1.29 B | 1.29 B | 1.29 B | 824 M | 824 M | 824 M | 824 M | 687 M | 687 M | 687 M | 687 M | 585 M | 585 M | 585 M | 585 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.96 B | 585 M | 1.41 B |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
10.9 B | $ 223.01 | -0.99 % | $ 395 B |  USA |
 |
Alpine Immune Sciences
ALPN
|
392 K | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
1.78 M | $ 4.68 | 1.85 % | $ 777 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
318 K | $ 3.38 | 3.21 % | $ 261 M | USA |
 |
Acasti Pharma
ACST
|
802 K | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
821 K | - | -15.15 % | $ 60.3 M |  Britain |
 |
Albireo Pharma
ALBO
|
3.27 M | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
234 K | - | - | $ 7.46 M |  Israel |
 |
Aptorum Group Limited
APM
|
62.2 K | $ 1.33 | -1.48 % | $ 7.25 M |  China |
 |
Amphastar Pharmaceuticals
AMPH
|
136 M | $ 25.76 | 0.19 % | $ 1.25 B | USA |
 |
Anika Therapeutics
ANIK
|
36 M | $ 9.53 | -1.19 % | $ 140 M | USA |
 |
Brickell Biotech
BBI
|
1.13 M | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
676 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
205 K | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
18.5 M | - | -7.31 % | $ 87 M | USA |
 |
Aytu BioScience
AYTU
|
31.2 M | $ 2.33 | 2.3 % | $ 14.6 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
1.65 M | - | -6.81 % | $ 3.04 B | USA |
 |
Baudax Bio
BXRX
|
335 K | - | 0.59 % | $ 63 K | USA |
 |
Catalyst Biosciences
CBIO
|
1.82 M | $ 15.32 | 5.73 % | $ 1.01 B | USA |
 |
ChromaDex Corporation
CDXC
|
5.23 M | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
18.1 M | $ 586.28 | 3.15 % | $ 44.4 B | USA |
 |
Cerus Corporation
CERS
|
29.8 M | $ 2.14 | 13.23 % | $ 395 M | USA |
 |
Caladrius Biosciences
CLBS
|
900 K | - | -16.75 % | $ 25.8 M | USA |
 |
Celldex Therapeutics
CLDX
|
700 K | $ 28.33 | 0.5 % | $ 1.82 M | USA |
 |
Clovis Oncology
CLVS
|
26.9 M | - | -7.23 % | $ 13 M | USA |
 |
Benitec Biopharma
BNTC
|
33 K | $ 12.91 | 0.78 % | $ 531 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
16.6 M | $ 60.38 | 0.11 % | $ 6.76 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
32 M | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
308 M | $ 11.55 | 8.86 % | $ 747 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
45.3 M | $ 10.89 | -0.09 % | $ 1.42 B | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
43.1 K | - | -5.68 % | $ 8.28 M | USA |